This #WorldHealthDay, we’re recognizing the importance of scientific progress in improving lives.
At Scribe, that mission continues to guide our work every day to advance novel #CRISPR-based genetic medicines for patients, starting with those with cardiovascular disease.
What does it take to build & lead a biotech today? Some valuable insights from our CBO Svetlana Lucas at the BioPioneers #WomensHistoryMonth event:
✅ Execute with utmost focus and discipline.
📈 Get comfortable being uncomfortable.
💡 Emotional intelligence is a differentiator.
To celebrate the start of spring, our team traded lab coats 🥼 for garden gloves for an afternoon of planting, propagating, and building out a community herb garden. 🌱
A fun way to welcome the season and spend time together outside the lab!
Addressing Lp(a) is central to our comprehensive #CRISPR-based strategy targeting key lipid drivers of cardiovascular disease. Our STX-1200 program is designed to be a one-time therapy to durably lower Lp(a) ➡️ www.scribetx.com/news/scribe-...
ACC/AHA guideline ➡️ newsroom.heart.org/news/accaha-...
Today is #LpaAwarenessDay. Do you know your Lp(a)?
Fewer than 1% of individuals with elevated levels of Lp(a) are aware of it. Now, a new @americanheart.bsky.social and @accintouch.bsky.social guideline recommends universal Lp(a) screening at least once in a lifetime. More in 🧵
#KnowLpa
The @nytimes.com covers these recommendations and the importance of long-term risk reduction: www.nytimes.com/2026/03/13/h...
At Scribe, we are developing STX-1150, a #CRISPR epigenetic silencing therapy designed to durably lower LDL-C by repressing PCSK9 without permanent genetic changes.
❤️🩹 New guideline from @accintouch.bsky.social, @americanheart.bsky.social, and other leading medical organizations reflects a key shift in cardiovascular care:
→ Earlier LDL-C testing
→ Targeting lower LDL-C levels based on risk
→ Greater focus on prevention over time
More in our thread 👇
Celebrate #WomensHistoryMonth this Thursday with a powerhouse panel of C-suite leaders, including our Chief Business Officer Svetlana Lucas.
Get your ticket to the BioPioneers event for insights on the future of biotech: luma.com/583ce9z8
#WomenInSTEM #WomenInScience
Scribe was created to expand #CRISPR's use beyond rare diseases, said CEO @benjaminloakes.bsky.social in an interview with @precmedonline.bsky.social.
Read about our progress in bringing our lead therapy for cardiovascular disease to the clinic 👉 www.precisionmedicineonline.com/business-new...
Join us at today's @keystonesymposia.bsky.social Precision Genome Engineering conference, where we're presenting our latest #EpigeneticEditing advances at 7:30pm.
📣 ADDing a Lock to Epigenome Editing: DNMT3A Allostery Enhances Specificity and Potency of #CRISPR-CasX-based Epigenetic Repressors
For this International Women's Day, our Scribe team came together to assemble care packages for women and communities in need. Thank you to everyone who showed up to #GiveToGain in support of women everywhere.
#InternationalWomensDay #WomenInSTEM
Interested in a deeper dive into the science and engineering behind STX-1150 and our ELXR epigenetic silencing tech?
Check out BioWorld’s feature on the scientific highlights for in vivo genetic medicine in 2025.
www.bioworld.com/articles/727...
Hypercholesterolemia is a major driver of cardiovascular disease. This BioWorld article covers our work to advance STX-1150 – designed to durably lower LDL-C via epigenetic silencing of PCSK9 – into the clinic and meaningfully change how #CVD is treated.
www.bioworld.com/articles/728...
Read the latest in @longevitytech.bsky.social about our second success milestone with @elilillyandcompany.bsky.social and the demonstration of “steady, disciplined progress toward a future where genetic medicine plays a central role in how we manage aging and chronic disease."
In Cardiovascular Business, Dave Fornell covers:
➡️ Our lead therapy STX-1150, designed to address the gap in treatment efficacy
➡️ Preclinical NHP data showing >50% LDL-C reduction maintained for ~18 months
➡️ Phase 1 study expected in mid-2026
cardiovascularbusiness.com/topics/clini...
At Scribe, we believe the standard of cardiovascular care today needs a paradigm shift. Cardiovascular Business spotlights our development of novel #CRISPR-based medicines that target the key lipid drivers of ASCVD – check out the article preview and link below. 👇
Read the @forbes.com daily cover story on Dr. Doudna: www.forbes.com/sites/amyfel...
And a 2023 feature on Scribe: www.forbes.com/sites/alexkn...
#CRISPR #GeneEditing #GeneticMedicine
Dr. Jennifer Doudna, Nobel laureate & Scribe co-founder, is one of America’s greatest innovators.
Our CEO and co-founder @benjaminloakes.bsky.social spoke with @forbes.com about her unmatched impact on science and medicine. Check out Dr. Doudna’s Forbes 250 profile in the links below 👇
We believe that purpose-built #CRISPR technologies can reach the potency & specificity needed for transformative medicines.
And this is the engineering philosophy we are applying in parallel across our wholly owned cardiometabolic pipeline. Read more 👇
www.businesswire.com/news/home/20...
We achieved a second success milestone with @elilillyandcompany.bsky.social in our collaboration to advance in vivo #CRISPR-based therapies for neurological and neuromuscular disorders.
Progress like this matters because patients cannot wait. More details in thread 🧵
#CRISPR #GeneEditing
Read the BiopharmaTrend article: www.biopharmatrend.com/news/scribe-...
Dive deeper into the science with our preprint: www.biorxiv.org/content/10.6...
@biorxivpreprint.bsky.social #CRISPR #Epigenetics #EpigeneticEditing
Our thanks to BiopharmaTrend for highlighting our newest preprint! We detail the engineering behind our ELXR epigenetic silencing tech – including a new control layer for the CasX-based epigenetic silencer.
The result: Improved precision for CRISPR-based therapeutics. Details ⬇️
Read more about our approach to improving cardiovascular health and longevity in this @longevitytech.bsky.social piece by @mrdannysullivan.bsky.social: longevity.technology/news/epigene...
#HeartDisease #OurHearts #HeartMonth
Can #CRISPR genetic medicine solve cardiovascular disease?
We’re advancing STX-1150 into first-in-human clinical trials to target LDL-C, one of the biggest drivers of heart disease, and reduce ASCVD risk without permanently changing the DNA. @longevitytech.bsky.social article below 👇
We’re proudly going red in support of National #WearRedDay and heart disease prevention ❤️🩹
Join us and learn more about what you can do to protect yourself and your loved ones by visiting: www.nhlbi.nih.gov/health/heart...
#HeartDisease #OurHearts #HeartMonth
🫀 At Scribe we're pioneering highly engineered CRISPR technologies and genetic medicines that leverage nature’s blueprint for better #HeartHealth.
Learn more about gene editing’s present and future from Nobel Prize winner and our co-founder Dr. Doudna: www.corememory.com/p/the-presen...
💡 During #AmericanHeartMonth, check out a thoughtful interview Scribe’s co-founder Jennifer Doudna recorded with Core Memory founder @ashleevance.bsky.social – highlighting how #CRISPR could shift current cardiometabolic disease treatment from symptom management to prevention.
Links ⬇️
Episode link 🔗 www.cellandgene.com/doc/building...
Apple Podcasts 🔗 podcasts.apple.com/us/podcast/b...
Spotify 🔗 open.spotify.com/episode/5jM4...
#CGT #GeneEditing #Epigenetics #HeartHealth
How do we engineer #CRISPR genetic medicines with the potency, specificity, and durability to treat not only rare disease, but also highly prevalent conditions?
Our CEO @benjaminloakes.bsky.social joined the Cell & Gene Podcast to discuss. Links in the thread 🎧
ICYMI learn more in @endpts.com about our plans to enter the clinic in mid-2026 with STX-1150, and our broader work to deliver on the potential of #CRISPR and nature’s blueprint for better cardiovascular health.
endpoints.news/scribe-thera...
#EpigeneticEditing #Epigenetics #HeartHealth #OurHearts
